Infliximab regulates monocytes and regulatory T cells in Kawasaki disease
First published: 15 March 2018
This article has been accepted for publication and undergone full peer review but has not been ... More
Abstract
Background
The effect of infliximab (IFX) on immune cells has not been fully reported in Kawasaki disease (KD). To investigate the mechanism of IFX in KD, we examined changes in the abundance of CD14+CD16+ activated monocytes, regulatory T cells (Treg), and T‐helper cell type 17 (Th17) cells following treatment with IFX.
Methods
We collected peripheral blood from patients with intravenous immunoglobulin (IVIG)‐resistant KD and analyzed the absolute counts of CD14+CD16+ monocytes, Treg cells (CD4+CD25+FOXP3+) and Th17 cells (CD4+IL‐17A+) by flow cytometry. We also measured changes in serum levels of soluble interleukin (IL)‐2 receptor, IL‐6, and tumor necrosis factor (TNF)‐α by enzyme‐linked immunosorbent assay.
Results
Treg cells and Th17 cells significantly increased after IFX treatment compared with baseline (126 ± 85 cells/μl vs. 62 ± 53 cells/μl, p <0.01; 100 ± 111 cells/μl vs. 28 ± 27 cells/μl, p <0.05). By contrast, CD14+CD16+ monocytes in a subgroup of patients selected above normal range significantly decreased following IFX treatment (72 ± 51 cells/μl vs. 242 ± 156 cells/μl, p <0.05). Serum levels of TNF‐α did not changed, but soluble IL‐2 receptor and IL‐6 decreased after IFX treatment.
Conclusion
IFX could down‐regulate activated monocytes and up‐regulate Treg cells towards the normal range. IFX treatment thus contributes to the process of attenuating inflammation in KD.
No comments:
Post a Comment